Instrument Inactif

Autres langues GENFIT Other OTC

Actions

GNFTF

FR0004163111

Recherche biotechnologique et médicale

Autres langues

03/08	GENFIT : Answers its Investors – Episode #3 - August 3, 2026
08/07	Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
03/07	Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement
02/07	GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
02/07	Genfit Announces U.S. Medicare Coverage and Future Reimbursement for Nashnext, A Non-Invasive Diagnostic Technology to Identify Patients with At-Risk Mash
29/06	Saudi Food and Drug Authority Approves Registration of Aikervo (Elafibranor) for Treatment of Primary Biliary Cholangitis
24/06	Genfit's Investigative Treatment for Bile Duct Cancer Shows Positive Results in Phase 1b Study
23/06	GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06	GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
15/06	GENFIT: June 15, 2026 Combined Shareholders Meeting Results
08/06	Genfit Launches Nashnext Test Powered by Nis4 Technology Via Labcorp Ondemand for Identification of At-Risk Mash
08/06	GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
25/05	GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
21/05	Genfit S.A. Reports Revenue Results for the First Quarter Ended March 31, 2026
21/05	Genfit March 31 cash and cash equivalents EUR 136.1 million
21/05	GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
15/05	Weekly Earnings Calendar: Focus on Nvidia and Walmart
11/05	GENFIT : Notice of the meeting – Shareholders' Meeting of June 15, 2026
11/05	GENFIT : Report of the Statutory Auditors on the Company Financial Statements for the year ended December 31, 2025
11/05	GENFIT : Report of the Statutory Auditors on the Consolidated Financial Statements for the year ended December 31, 2025
11/05	GENFIT : Special Report of the Board of Directors on Stock Options to the Combined Shareholders’ Meeting of June 15, 2026
11/05	GENFIT : Special Report of the Board of Directors on Free Shares to the Combined Shareholders’ Meeting of June 15, 2026
11/05	GENFIT : Report of the Board of Directors to the Combined Shareholders’ Meeting of June 15, 2026
11/05	GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
24/04	GENFIT : Investor Presentation - April 2026